| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4c43714fa0c0aecdd51a182822d3d085
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7f95b1a5b6dde096c3ea588f130ea847
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_634d6c74e069a791cab9ff0273d6955e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_346279f449fcb24dca07aad8176b1290
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_10f306c65d25e8e5c58ff9052873e87b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1641
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2031
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1617 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1682
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2077
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-26 |
| filingDate |
2007-01-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a2a8a60134e15d660132762dc164a40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e5b93f87d554c97d56c1bd6cc49f427
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba82e5215ea429de09f37fc1d5b1c682
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60887bf2a47b6134d9393533c208a6d7 |
| publicationDate |
2007-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2007077581-A2 |
| titleOfInvention |
Pharmaceutical compositions |
| abstract |
A novel solid oral dosage form comprising a therapeutically effective amount of hydrophobic pharmacological active ingredient and at least one particle separating agent preferably selected from a class of wetting agents, prepared without or with minimum amount of a disintegrating agent. The hydrophobic pharmacological active ingredient active ingredient belongs to the class of angiotensin receptor blocking agents preferably is valsartan optionally in combination with hydrochlorothiazide. The active ingredient may also be a class of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors preferably atorvastatin. The ratio of hydrophobic active ingredient to particle separating agent is about 20:1 to about 1 :20. The process for the preparation of the novel solid oral dosage form comprises treating a hydrophobic active ingredient with at least one particle separating agent, and incorporating the treated hydrophobic active ingredient into a solid dosage form. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011171140-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9675585-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10010529-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2165702-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103349656-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2341773-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008084504-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2341773-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011102702-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9687475-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008084504-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103349656-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009108824-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8795634-B2 |
| priorityDate |
2006-01-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |